Intellectual property and trade


Incredible India truck in front of Whitehouse Photograph by Ken Cedeno
Learn more
#HandsOffOurMeds Intellectual property and trade generic medicines

Don't shut down the pharmacy of the developing world

Take action now!

Urge Indian Prime Minister Modi to protect India’s production of lifesaving affordable generic medicines. 👇

MSF to @PMOIndia: Protect the pharmacy of the developing world! #HandsOffOurMeds

Back to top ↑

Médecins Sans Frontières (MSF) relies heavily on generic medicines made in India to carry out its medical work in more than 60 countries. But the ‘pharmacy of the developing world’ is under attack from the US, the EU, Japan and others who are protecting multinational pharmaceutical profits over peoples’ lives.

Don't shut down the pharmacy of the developing world!

Millions of people around the world rely on affordable medicines made in India to stay alive.


A Matter of Life & Death: The Role of Patents in Access to Essential Medicines

MSF briefing for the 4th WTO Ministerial Conference in Doha, Qatar. Includes articles on how generic competition brings down drug prices, TRIPS safeguards in use in developed countries, and why donations won’t solve the access crisis, among others. Ends with recommendations to the WTO members to support a pro-public health interpretation of the TRIPS Agreement.

Read more here.

Intellectual property and trade Issue brief Doha Declaration

The Role of Patents in Access to Essential Medicines


Opposing patent application for bedaquiline formulation in India

In an effort to make lifesaving drugs accessible to all people, civil society organisations around the world have worked tirelessly to remove patent barriers on drugs for the treatment of cancer, HIV and hepatitis C. In India, the largest manufacturer of affordable drugs for the developing world, the struggle to scale up access to medicines for drug-resistant tuberculosis (DR-TB) is now at a decisive stage. Médecins Sans Frontières (MSF) and civil society organisations in the country are supporting a patent challenge filed by two TB survivors in order to prevent pharmaceutical corporation Johnson & Johnson (J&J) from extending its monopoly on the core DR-TB drug bedaquiline.

drug-resistant TBtuberculosis bedaquiline India Intellectual property and tradeTuberculosis Technical brief patent opposition
XDR-TB patient Nischaya, at home the Ambedkar Nagar area of Mumbai, with her TB medication. Photography by Atul Loke
Subscribe to Intellectual property and trade